171 related articles for article (PubMed ID: 31264531)
1. Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).
Facchinetti F; Pilotto S; Metro G; Baldini E; Bertolaccini L; Cappuzzo F; Delmonte A; Gasparini S; Inno A; Marchetti A; Passiglia F; Puma F; Ricardi U; Rossi A; Crinò L; Novello S
Tumori; 2019 Jul; 105(5_suppl):3-14. PubMed ID: 31264531
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Passiglia F; Pilotto S; Facchinetti F; Bertolaccini L; Del Re M; Ferrara R; Franchina T; Malapelle U; Menis J; Passaro A; Ramella S; Rossi G; Trisolini R; Novello S
Crit Rev Oncol Hematol; 2020 Feb; 146():102858. PubMed ID: 31918343
[TBL] [Abstract][Full Text] [Related]
3. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
Barni S; Maiello E; Di Maio M; Ardizzoni A; Cappuzzo F; Maranzano E; Novello S; Bennati C; Ori A; Rizzoli S; Crinò L;
Lung Cancer; 2015 Nov; 90(2):234-42. PubMed ID: 26314614
[TBL] [Abstract][Full Text] [Related]
4. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).
Vitale MG; Bracarda S; Cosmai L; Crocetti E; Di Lorenzo G; Lapini A; Mandressi A; Martorana G; Masini C; Montironi R; Ortega C; Passalacqua R; Porta C; Procopio G; Sepe P; Romano L; Pappagallo GL; Conti G; Guida M; Martignoni G; Nolè F; Pignata S; Gori S; Cartenì G
Tumori; 2019 Jul; 105(4_suppl):3-12. PubMed ID: 31264522
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Passiglia F; Bertolaccini L; Del Re M; Facchinetti F; Ferrara R; Franchina T; Malapelle U; Menis J; Passaro A; Pilotto S; Ramella S; Rossi G; Trisolini R; Novello S
Crit Rev Oncol Hematol; 2020 Apr; 148():102862. PubMed ID: 32062311
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Queirolo P; Cinquini M; Argenziano G; Bassetto F; Bossi P; Boutros A; Clemente C; de Giorgi V; Del Vecchio M; Patuzzo R; Pennachioli E; Peris K; Quaglino P; Reali A; Zalaudek I; Spagnolo F
ESMO Open; 2024 May; 9(5):103005. PubMed ID: 38688192
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
14. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
Dempke WC; Sellmann L; Fenchel K; Edvardsen K
Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
[TBL] [Abstract][Full Text] [Related]
16. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
Soo RA; Anderson BO; Cho BC; Yang CH; Liao M; Lim WT; Goldstraw P; Mok TS;
Lancet Oncol; 2009 Nov; 10(11):1102-10. PubMed ID: 19880064
[TBL] [Abstract][Full Text] [Related]
17. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
Gobbini E; Galetta D; Tiseo M; Graziano P; Rossi A; Bria E; Di Maio M; Rossi G; Gregorc V; Riccardi F; Scotti V; Ceribelli A; Buffoni L; Delmonte A; Franchina T; Migliorino MR; Cortinovis D; Pisconti S; Bordi P; Catino A; Maiello E; Arizio F; Novello S;
Lung Cancer; 2017 Sep; 111():30-37. PubMed ID: 28838394
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
